We are committed to partnering with organizations from around the world to develop innovative medicines that will transform patients' lives. We are selective in the number and type of alliances that we forge and believe that partnerships are only as successful as the combined commitment of both organizations. Our team benefits from significant experience working with global pharmaceutical and biotech companies and has pioneered many of the collaboration models in China.
Strategic partner for Greater China
We believe the combination of our management’s innovative drug R&D experience, our knowledge of the changing regulatory landscape in China, our manufacturing capabilities, and the commercial capabilities we are developing makes us a trusted partner of choice for global biopharmaceutical companies seeking to access the China market.
The recognition of our team as a partner of choice is evidenced by our partnerships with global biopharmaceutical companies, including Tesaro, Paratek and Bristol-Myers Squibb, that out-licensed their clinical products to Zai Lab. We will continue actively seeking high quality drug candidates and evaluating inbound interest we receive. We are currently in active negotiations for multiple promising assets to further our ambitions to bring innovative medicines to the China market.
Licensing of programs with global rights
Our team's global innovative drug R&D experience has also attrated a lot of partners for global product development. We have a track record of in-licensing the global rights of drug candidates from leading global biopharmaceutical companies such as GSK, Sanofi and UCB. We will continue seeking new in-licensing opportunities which grant us the global rights for differentiated drug candidates.
Contact us at: BD@zailaboratory.com